Next-Gen Therapies: Unlocking the Potential of Bispecific ADCs

As the competition in both traditional ADC and bispecific sectors intensifies, bispecific ADCs (BsADCs) are emerging as a key differentiator for developers looking to stand out. In 2023 alone, a record 25 BsADCs were publicly disclosed and 4 entered clinical trials, marking an incredible 50% annual growth rate over the past six years!

Our infographic reveals how these next-generation therapies are overcoming the limitations of existing modalities. Download your copy to leverage Beacon’s powerful data and seize the immense opportunity this field has to offer.

Bispecific ADCs Infographic

Covered in this Infographic:

  • Drug Status and Trial Phases: Understand the current development stages of BsADCs and their progression through various trial phases.
  • Developer Locations: Visualize the geographic distribution of developers working on these drugs.
  • Benefits of BsADCs: Explore the advantages of utilizing this cutting-edge therapy.
  • Top Targets: Identify the key targets in this field and the strategies being used for target selection.

You May Also Be Interested In…

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration

Menu
Search Icon
Close Icon
Search